MBRX moleculin.com: Enterprise Value to EBITDA Ratio

Brandmark of Moleculin Biotech, Inc. (MBRX)

Moleculin Biotech, Inc. (MBRX) develops advanced small molecules to combat resistant forms of cancer. The development of new anthracyclines relies on partnerships with scientific centers, which accelerates clinical implementation. The asset value of 0.00 reflected in the GURU.Markets chart correlates with the expansion of the clinic network in the US and EU, where the low toxicity of the drug Annamycin promotes patient retention in trials.

MBRX Moleculin Biotech Inc: Company Value to Operating Income Before Depreciation Ratio in the range 11/23/2025 - 11/12/2026

Metric breakdowns and analytics for moleculin.com (MBRX)

- stock price and consensus target price:
Stock Quotes Moleculin Biotech|MBRX - Average Forecast Price
- company stock capitalization data:
Market Valuation MBRX|MBRX - Value Adjusted for Debt and Cash
- business book valuation details:
Net Assets per Single Share Moleculin Biotech|MBRX - Net Asset Value|Market Value to Book Value Ratio moleculin.com|MBRX - Aggregate Company Assets
- debt and solvency information:
Total Debt to Capital Moleculin Biotech, Inc.|MBRX - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Moleculin Biotech|MBRX - Company Cumulative Indebtedness|Debts to Book Capitalization MBRX|MBRX - Long-Term Liabilities|Company Short-Term Debt Moleculin Biotech|Quick Liquidity moleculin.com
- business earnings and investment ratios data:
MBRX - Final Profit|Expected Profit Moleculin Biotech, Inc.|MBRX - Price to Earnings Ratio|Future Price to Earnings Moleculin Biotech|MBRX - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MBRX|MBRX - Operating profit before deduction of amortization|Earnings per share for the last twelve months Moleculin Biotech|MBRX - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months moleculin.com|MBRX - Earnings per share growth in current year|Earnings growth forecast for next year Moleculin Biotech, Inc.
General company analysis:Moleculin MBRX
Product sample of Moleculin Biotech Inc

The EV/EBITDA multiple determines the total value of the business, including debt obligations, relative to operating profit before depreciation and amortization, allowing for an assessment of cash flow generation efficiency. For Moleculin Biotech, Inc. (MBRX), which is burdened by development costs for leukemia drugs, the company's trend EV/EBITDA level reflects a market discount for clinical trial risks, serving as an indicator of potential asset revaluation upon a shift in the cycle phase.

Direct competitors

Geron Corp. - Enterprise Value to EBITDA Ratio|Nanobiotix Group (NBTX) - Company Value to EBITDA|BCYC: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation CTMX (cytomx.com)|perspectivetherapeutics.com (CATX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio GNLX (Genelux)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Molecular Partners AG|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ONCY|EV/EBITDA Multiple LSTA|EV/EBITDA Multiple galeratx.com (GRTX)|Molecular Templates, Inc. - Enterprise Value to EBITDA Ratio